With reference to the article within the January 2025 challenge of the Journal entitled “Medical effectiveness and security of dupilumab in sufferers with persistent obstructive pulmonary illness: A 7-year population-based cohort research” (J Allergy Clin Immunol 2025;155:219-22.e1), the authors want to appropriate an error within the textual content. The road ought to learn “The current COURSE trial, a part IIa scientific trial, didn’t reveal scientific advantages in decreasing AE charges in sufferers with moderate-to-severe COPD and blood eosinophil counts greater than 0.30 × 103/μL who acquired with the anti-TSLP remedy tezepelumab versus with placebo over 52 weeks (fee ratio = 0.54 [95% CI = 0.25 to 1.15]).” The correction to the textual content doesn’t have an effect on the outcomes or conclusions of the article.
Trending Merchandise
